the effect of resveratrol on the gingival health of diabetic patients

The effect of resveratrol supplementation on clinical parameters and inflammatory markers in diabetic patients with chronic periodontitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171015036782N9

Enrollment

Registered

2023-02-14

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Chronic periodontitis. Condition 2: diabetes. Chronic periodontitis Unspecified diabetes mellitus

Interventions

Intervention 1: Intervention group: 26 diabetics with moderate to severe chronic periodontitis will be selected after examination and diagnosis of periodontal symptoms and according to the entry and e

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 30-60 years Body mass index (BMI) 18.5 to 30 kg/m2 Patients with confirmed and controlled diabetes mellitus (minimum one year and maximum 5 years since diagnosis) 9>HBA1C Moderate to severe periodontal disease

Exclusion criteria

Exclusion criteria: Patient non-cooperation Diabetes complications such as kidney failure No systemic disease taking medication Pregnancy and breastfeeding smoking Allergy to black grapes or blueberries

Design outcomes

Primary

Measure	Time frame
Probing depth. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: With Probe Williams.;Clinical Attachment Level. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: With Probe Williams.;Plaque index. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: The percentage of plaque accumulation around the surfaces of the teeth after evaluation with a revealing substance.;Bleeding index. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: Percentage of bleeding around all teeth after 30 seconds following probing.;IL-1ß. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: The amount of interleukin IL-1ß per unit volume of saliva.;IL-8. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: The amount of interleukin IL-8 per unit volume of saliva.	—

Measure

Time frame

Probing depth. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: With Probe Williams.;Clinical Attachment Level. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: With Probe Williams.;Plaque index. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: The percentage of plaque accumulation around the surfaces of the teeth after evaluation with a revealing substance.;Bleeding index. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: Percentage of bleeding around all teeth after 30 seconds following probing.;IL-1ß. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: The amount of interleukin IL-1ß per unit volume of saliva.;IL-8. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: The amount of interleukin IL-8 per unit volume of saliva.

—

Secondary

Measure	Time frame
HBA1C. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: blood test.;FBS. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: From the kit by the enzymatic method.;Body mass index. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: BMI is calculated using height and weight. BMI = weight (kilograms) / (height) 2 (square meters).	—

Measure

Time frame

HBA1C. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: blood test.;FBS. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: From the kit by the enzymatic method.;Body mass index. Timepoint: At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study. Method of measurement: BMI is calculated using height and weight. BMI = weight (kilograms) / (height) 2 (square meters).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazanin Roqani Dehkordi

Yazd University of Medical Sciences

nazanin.roghani91@gmail.com+98 35 2417 3393

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026